

Special Issue

Cirrhosis and Complication: Treatment and Prognosis

Message from the Guest Editor

Cirrhosis represents the end stage of chronic liver disease because of different causes, including viral hepatitis, autoimmune and genetic illnesses, alcohol abuse and metabolic disorders. The term cirrhosis includes clinical conditions with different grades of severity depending on onset of clinical complications, including gastrointestinal bleeding, hepatic encephalopathy (HE) and ascites. Generally, when the complications linked to the portal hypertension appear, the liver damage from cirrhosis cannot be reversed. However, specific treatments can stop or delay further progression and reduce complications. This Special Issue will be a collection of manuscripts providing an overview of the current research of treatment and prognosis in cirrhosis and complications. The aim of this Special Issue is to provide a complete overview of the treatment and complications in the cirrhosis progression, finding any possible predictor of clinical outcome including specific treatment, lifestyle changes, involves molecular mechanisms, new drugs or surgery, and bacterial infections in cirrhosis. We welcome the submission of original papers and reviews regarding cirrhosis.

Guest Editor

Prof. Dr. Irene Cacciola

Department of Clinical and Experimental Medicine, University of Messina and University Hospital of Messina, 98125 Messina, Italy

Deadline for manuscript submissions

closed (20 May 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/126508

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).